Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Innere Medizin I - Onkologie, Hämatologie, Klin. Immunologie und Rheumatologie
Leitung: Priv. Doz. Dr. med. Lorenz Thurner
Sie befinden sich hier: >> Startseite >> Klinische Zentren und Einrichtungen >> Klinische Zentren und Einrichtungen am UKS >> Medizinische Kliniken >> Innere Medizin I >> Akutelle Publikationen

Aktuelle Publikationen

Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis.

Christofyllakis K, Pföhler C, Bewarder M, Müller CSL, Thurner L, Rixecker T, Vogt T, Stilgenbauer S, Yordanova K, Kaddu-Mulindwa D.

Front Oncol. 2021 Feb 18;10:637161. doi: 10.3389/fonc.2020.637161. https://pubmed.ncbi.nlm.nih.gov/33680957/

 

Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls.

Kaddu-Mulindwa D, Thurner L, Bewarder M, Murawski N, Ahlgrimm M, Pfuhl T, Gärtner B, Smola S, Stilgenbauer S.Kaddu-Mulindwa D, et al.
Infect Agent Cancer. 2021 Feb 24;16(1):17. doi: 10.1186/s13027-021-00356-5.
https://pubmed.ncbi.nlm.nih.gov/33627114/

 

LRPAP1-autoantibodies in mantle cell lymphoma are associated with superior outcome.

Thurner L, Fadle N, Bittenbring JT, Regitz E, Schuck R, Cetin O, Stuhr A, Rixecker T, Murawski NM, Poeschel V, Kaddu-Mulindwa D, Preuss KD, Stilgenbauer S, Hermine O, Kluin-Nelemans JC, Hartmann S, Dreyling M, Pott C, Bewarder M, Hoster E.Thurner L, et al.
Blood. 2021 Jan 29:blood.2020008835. doi: 10.1182/blood.2020008835. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33513604/

 

Lymphocyte Predominant Cells Detect Moraxella Catarrhalis-Derived Antigens in Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Lorenz Thurner, Sylvia Hartmann, Natalie Fadle, Evi Regitz, Maria Kemele, Yoo-Jin Kim, Rainer Maria Bohle, Anna Nimmesgern, Lutz von Müller, Volkhard A J Kempf, Marc A Weniger, Frank Neumann, Nadine Schneider, Martine Vornanen, Christer Sundström, Laurence de Leval, Andreas Enger, Dennis A Eichenauer, Ralf Küppers, Klaus-Dieter Preuss, Martin-Leo Hansmann, Michael Pfreundschuh.

Nature Communications. 2020 May 18;11(1):2465.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235000/

 

Feasibility and Safety of CD19 CAR T Cell Treatment for B-cell Lymphoma Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Maria-Luisa Schuber, Sascha Dietrich, Stephan Stilgenbauer, Anita Schmitt, Petra Pavel, Alexander Kunz, Andrea Bondong, Mandy Wegner, Peter Stadtherr, Susanne Jung, Anthony D Ho, Carsten Müller-Tidow, Michael Schmitt, Peter Dreger 

Biol Blood Marrow Transplant 2020 May 5; S083-879(20)30258-5.

https://pubmed.ncbi.nlm.nih.gov/32422254/

 

 

Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential.

Bewarder M, Held G, Thurner L, Stilgenbauer S, Smola S, Preuss KD, Carbon G, Bette B, Christofyllakis K, Bittenbring JT, Felbel A, Hasse A, Murawski N, Kaddu-Mulindwa D, Neumann F.

Cancer Immunol Immunother 2020 Apr 16.

https://pubmed.ncbi.nlm.nih.gov/32300857/

 

International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a

comparison of IPI, R-IPI and NCCN-IPI.

Ruppert AS, Dixon JG, Salles GA, Wall A, Cunningham D, Poeschel V, Haioun C,

Tilly H, Ghesquieres H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N.

Blood 2020 Mar 13. pii: blood.2019002729.

https://pubmed.ncbi.nlm.nih.gov/32232482/

 

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.

Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R; Emed Demonstrator Project; German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL).

Leukemia 2020 Feb;34(2):543-552.

https://pubmed.ncbi.nlm.nih.gov/31530861/

 

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: A Young SIOG review paper.

Neuendorff NR, Loh KP, Mims AS, Christofyllakis K, Soo WK, Bölükbasi B, Oñoro-Algar C, Hundley WG, Klepin HD (2020) Blood Adv 4:762–775

https://pubmed.ncbi.nlm.nih.gov/32097461/

 

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.

Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance.

Lancet 2020 Dec 21;394(10216):2271-2281.

https://pubmed.ncbi.nlm.nih.gov/31868632/

 

LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.

Thurner L, Hartmann S, Fadle N, Kemele M, Bock T, Bewarder M, Regitz E, Neumann F, Nimmesgern A, von Müller L, Pott C, Kim YJ, Bohle RM, Wasik M, Schuster SJ, Hansmann ML, Preuss KD, Pfreundschuh M.

Leukemia 2019 Jan;33(1):148-158.

https://pubmed.ncbi.nlm.nih.gov/29955130/

 

 

Safety and feasibility of electrical muscle stimulation in patients undergoing autologous and allogeneic stem cell transplantation or intensive chemotherapy.

Bewarder M, Klostermann A, Ahlgrimm M, Bittenbring JT, Pfreundschuh M, Wagenpfeil S, Kaddu-Mulindwa D.

Support Care Cancer 2019 Mar;27(3):1013-1020. doi: 10.1007/s00520-018-4390-z. Epub 2018 Aug 9.

https://pubmed.ncbi.nlm.nih.gov/30094730/

 

Venetoclax and Obinutuzumab in Patients With CLL and Coexisting Conditions

Kirsten Fischer , Othman Al-Sawaf , Jasmin Bahlo , Anna-Maria Fink , Maneesh Tandon , Mark Dixon , Sandra Robrecht , Simon Warburton , Kathryn Humphrey , Olga Samoylova , Anna M Liberati , Javier Pinilla-Ibarz , Stephen Opat , Liliya Sivcheva , Katell Le Dû , Laura M Fogliatto , Carsten U Niemann , Robert Weinkove , Sue Robinson , Thomas J Kipps , Sebastian Boettcher , Eugen Tausch , Rod Humerickhouse , Barbara Eichhorst , Clemens-Martin Wendtner , Anton W Langerak , Karl-Anton Kreuzer , Matthias Ritgen , Valentin Goede , Stephan Stilgenbauer , Mehrdad Mobasher , Michael Hallek 

N Engl J Med 2019 Jun 6;380(23):2225-2236.

https://pubmed.ncbi.nlm.nih.gov/31166681/

 

Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.

Thurner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Hartmann S, Hansmann ML, Mackensen A, Schäfer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M.

Blood 2018 Dec 27;132(26):2744-2753.

https://pubmed.ncbi.nlm.nih.gov/30249786/

 

 

The riddle of lymphoma BCR-antigenes.

Thurner L, Hartmann S, Preuss KD, Bewarder M.

Oncotarget 2018 Nov 9;9(88):35805-35806.

https://pubmed.ncbi.nlm.nih.gov/30533194/